Detalles de la búsqueda
1.
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Mod Pathol
; 37(4): 100445, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341130
2.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325276
3.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol
; 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38501262
4.
Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary.
Int J Gynecol Cancer
; 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38627034
5.
Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
Gynecol Oncol
; 178: 96-101, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37839314
6.
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database.
J Surg Oncol
; 128(1): 111-118, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36975108
7.
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
J Pathol
; 256(4): 388-401, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897700
8.
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.
Int J Gynecol Cancer
; 33(7): 1083-1089, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001891
9.
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.
Int J Gynecol Cancer
; 33(5): 734-740, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759002
10.
Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study.
Int J Gynecol Cancer
; 33(1): 42-49, 2023 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36104079
11.
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Int J Gynecol Cancer
; 33(12): 1966-1969, 2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37935524
12.
The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Int J Gynecol Cancer
; 33(8): 1304-1309, 2023 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37208019
13.
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).
Int J Gynecol Cancer
; 33(2): 223-230, 2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36631151
14.
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
Br J Cancer
; 126(7): 1047-1054, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34923575
15.
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Gynecol Oncol
; 166(2): 334-343, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35738917
16.
Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Gynecol Oncol
; 163(3): 569-577, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34565600
17.
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Int J Gynecol Cancer
; 31(4): 617-622, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33318079
18.
Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
Arch Gynecol Obstet
; 304(4): 975-984, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33710393
19.
Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
Arch Gynecol Obstet
; 304(4): 1021-1032, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33661392
20.
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group.
Arch Gynecol Obstet
; 304(6): 1541-1549, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34287678